Patents Assigned to GLX Analytix ApS
  • BIOMARKERS FOR MULTIPLE SCLEROSIS
    Publication number: 20260153508
    Abstract: Described herein are biomarkers for the prediction of the risk of developing and/or having multiple sclerosis (MS), as well as staging/subtyping MS and methods for evaluating treatment protocols for MS and for assisting in the prognosis of MS. Also described herein are biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and even more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).
    Type: Application
    Filed: October 2, 2025
    Publication date: June 4, 2026
    Applicant: GLX Analytix ApS
    Inventors: Brian William Della Valle, Casper Hempel, Marie Agnete Larsen
  • Biomarkers for multiple sclerosis
    Patent number: 12461098
    Abstract: Described herein are biomarkers for the prediction of the risk of developing and/or having multiple sclerosis (MS), as well as staging/subtyping MS and methods for evaluating treatment protocols for MS and for assisting in the prognosis of MS. Also described herein are biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and even more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).
    Type: Grant
    Filed: April 23, 2024
    Date of Patent: November 4, 2025
    Assignee: GLX Analytix ApS
    Inventors: Brian William Della Valle, Casper Hempel, Marie Agnete Larsen
  • Biomarkers for multiple sclerosis
    Patent number: 11994519
    Abstract: The present invention relates to biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and teven more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 28, 2024
    Assignee: GLX Analytix ApS
    Inventors: Brian William Della Valle, Casper Hempel, Marie Agnete Larsen